Revolution stock price target cut to $59 at Needham

On Thursday, Needham analysts adjusted their financial outlook on Revolution (NASDAQ:RVMD), a $7.48 billion market cap biotech company, reducing the price target to $59 from the previous $60 while maintaining a Buy rating on the stock. The revision followed Revolution’s fourth-quarter earnings report, which revealed a loss per share of $1.12, exceeding the consensus estimate of a $0.99 loss. The larger-than-expected loss was attributed to increased research and development expenses, totaling $24.7 million compared to the consensus forecast. According to InvestingPro analysis, Revolution currently appears overvalued based on its proprietary Fair Value calculations.

Looking ahead to 2025, Revolution’s management provided guidance predicting a net loss between $840 million and $900 million. Despite these projected losses, InvestingPro data shows the company maintains strong liquidity with a current ratio of 14.24 and holds more cash than debt on its balance sheet. A significant highlight from the earnings update was the announcement of two additional registrational trials for the company’s investigational drug daraxonrasib, targeting earlier lines of pancreatic ductal adenocarcinoma (PDAC). These trials, including a first-line PDAC study and an adjuvant setting for resectable PDAC, are slated to begin in the second half of 2025.

Needham analysts anticipate a positive market response to the expansion of daraxonrasib’s trials, particularly the adjuvant setting for PDAC, as it potentially broadens the total addressable market (TAM) for the drug. Approximately 15 to 20 percent of newly diagnosed PDAC patients present with a tumor that is resectable, indicating a sizeable patient population for daraxonrasib’s use.

In light of the latest earnings and management’s guidance, Needham has updated its financial model for Revolution. The firm has accounted for the increased projected expenses for 2025, which led to the adjustment of the price target to $59. Notably, broader analyst consensus remains strongly bullish, with price targets ranging from $60 to $87. Investors are also advised to watch for forthcoming clinical data on zoldonrasib (RMC-9805) as a monotherapy, expected in the second quarter of 2025, and in combination therapy anticipated in the second and third quarters of the same year. For deeper insights into Revolution’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Revolution Medicines Inc . reported its financial results for the fourth quarter of 2024, highlighting a net loss of $194.6 million, which marks an increase from the $161.5 million loss in the same quarter of the previous year. Despite this, the company maintains a robust cash position of $2.3 billion, supported by $823 million from an equity offering. Revolution Medicines is advancing its clinical-stage RAS inhibitors, with plans for pivotal trials and potential regulatory approvals in 2025. The company projects a GAAP net loss between $840 million and $900 million for 2025, reflecting increased expenses associated with clinical development and commercial preparation efforts.

Additionally, Revolution Medicines is actively preparing for global expansion and is exploring combination therapies to enhance its treatment offerings. Analyst firms such as UBS and JPMorgan have shown interest in the company’s strategic focus on expanding treatment options for RAS-addicted cancers. The company’s executives have emphasized their commitment to revolutionizing cancer treatment through innovative targeted medicines and have outlined strategic priorities for the upcoming year. These developments underscore Revolution Medicines’ ongoing efforts to establish a leading position in the oncology-focused biopharmaceutical industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.